The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Director dealings: Hikma gets shot in the arm as chief tops up

Wed, 20th Apr 2016 16:38

(ShareCast News) - Hikma Pharmaceuticals's chief Said Darwazah boosted his stake in the generic drugs firm on Wednesday to 5.49% through the acquisition of 30,000 shares at an individual price of 2,271p.The transaction was carried out by Vidacos Nominees on behalf of Darhold Limited, in which Darwazah holds an equity stake.On 8 April, the US Food and Drug Administration accepted Hikma's new drug application for fluticasone propionate and salmeterol inhalation powder, its version of GlaxoSmithKline's Diskus anti-asthma treatment.Previously, on 16 March, the company released full-year results which revealed a 4.0% rise in operating profits to $409m."While FY'2016 is likely to be a transitional year, FY'2017 is expected to show momentum with growth supported by new product launches. We stay with our Strong Buy recommendation," analysts at Charles Stanley said in a research report commenting on the results.The FTSE-250 listed company's shares finished 0.88% higher on Wednesday at 2,300p, giving it a market capitalisation of £5,506, not far from its 52-week highs of 2,490p hit on 21 September 2015.Top Director BuysHikma Pharmaceuticals (HIK)Director name: Darwazah,SaidAmount purchased: 30,000 @ 2,271.00pValue: £681,299.97Bailey (c.h.) (BLEY)Director name: Bailey,Charles HAmount purchased: 69,600 @ 150.00pValue: £104,400.00Jupiter European Opportunities Trust (JEO)Director name: Wallinger,JohnAmount purchased: 10,000 @ 540.50pValue: £54,050.00Chrysalis Vct (CYS)Director name: Harkness,PeterAmount purchased: 42,500 @ 60.00pValue: £25,500.00Hansteen Holdings (HSTN)Director name: Rough,DavidAmount purchased: 7,500 @ 106.85pValue: £8,013.75Hansteen Holdings (HSTN)Director name: Rough,DavidAmount purchased: 7,500 @ 106.85pValue: £8,013.75Jupiter European Opportunities Trust (JEO)Director name: Sutch,Andrew LAmount purchased: 462 @ 540.12pValue: £2,495.38Pennon Group (PNN)Director name: Davy ,Susan Amount purchased: 15 @ 818.44pValue: £122.77Top Director Sells

Related Shares

More News
3 May 2024 09:14

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

26 Apr 2024 13:36

UK dividends calendar - next 7 days

25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth readi...

25 Apr 2024 10:15

Hikma Pharmaceuticals backs outlook after making strong start to 2024

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reported an encouraging start to the year supported by all three business segments.

25 Apr 2024 08:01

Hikma delivers strong Q1, holds on to guidance

(Sharecast News) - Pharmaceuticals group Hikma said it has made a "strong and encouraging start" to 2024, with all three business segments performing ...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.